10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2022 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 17, 2023) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Net Sales | $ 43,653 | 43,075 | 34,608 |
| Cost of products sold, excluding amortization of intangible assets | 19,142 | 18,537 | 15,003 |
| Amortization of intangible assets | 2,013 | 2,047 | 2,132 |
| Research and development | 2,888 | 2,742 | 2,420 |
| Selling, general and administrative | 11,248 | 11,324 | 9,696 |
| Total Operating Cost and Expenses | 35,291 | 34,650 | 29,251 |
| Operating Earnings | 8,362 | 8,425 | 5,357 |
| Interest expense | 558 | 533 | 546 |
| Interest income | (183) | (43) | (46) |
| Net foreign exchange (gain) loss | 2 | 1 | (8) |
| Other (income) expense, net | (321) | (277) | (103) |
| Earnings from Continuing Operations Before Taxes | 8,306 | 8,211 | 4,968 |
| Taxes on Earnings from Continuing Operations | 1,373 | 1,140 | 497 |
| Earnings from Continuing Operations | 6,933 | 7,071 | 4,471 |
| Net Earnings from Discontinued Operations, net of taxes | 0 | 0 | 24 |
| Net Earnings | 6,933 | 7,071 | 4,495 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 3.94 | 3.97 | 2.51 |
| Discontinued Operations (in dollars per share) | 0.00 | 0.00 | 0.01 |
| Net Earnings (in dollars per share) | 3.94 | 3.97 | 2.52 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 3.91 | 3.94 | 2.49 |
| Discontinued Operations (in dollars per share) | 0.00 | 0.00 | 0.01 |
| Net Earnings (in dollars per share) | 3.91 | 3.94 | 2.50 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,753 | 1,775 | 1,773 |
| Dilutive Common Stock Options (in shares) | 11 | 14 | 13 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | 1,764 | 1,789 | 1,786 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 3 | 0 | 9 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2022 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 17, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Net Earnings | $ 6,933 | 7,071 | 4,495 |
| Foreign currency translation gain (loss) adjustments | (894) | (980) | 65 |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $330 in 2022, $340 in 2021 and $(79) in 2020 | 1,177 | 1,201 | (331) |
| Net gains (losses) on derivative instruments designated as cash flow hedges, net of taxes of $11 in 2022, $63 in 2021 and $(87) in 2020 | 40 | 351 | (215) |
| Other Comprehensive Income (Loss) | 323 | 572 | (481) |
| Comprehensive Income | 7,256 | 7,643 | 4,014 |
| Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation (loss) adjustments | (6,733) | (5,839) | (4,859) |
| Net actuarial (losses) and prior service (cost) and credits | (1,493) | (2,670) | (3,871) |
| Cumulative gains (losses) on derivative instruments designated as cash flow hedges | 175 | 135 | (216) |
| Accumulated other comprehensive income (loss) | (8,051) | (8,374) | (8,946) |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2022 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 17, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 6,933 | 7,071 | 4,495 |
| Adjustments to reconcile earnings to net cash from operating activities | |||
| Depreciation | 1,254 | 1,491 | 1,195 |
| Amortization of intangible assets | 2,013 | 2,047 | 2,132 |
| Investing and financing losses, net | 215 | 55 | 425 |
| Share-based compensation | 685 | 640 | 546 |
| Trade receivables | (68) | (383) | (924) |
| Inventories | (1,413) | (456) | (493) |
| Prepaid expenses and other assets | (75) | (312) | (627) |
| Trade accounts payable and other liabilities | 420 | 1,288 | 1,766 |
| Income taxes | (383) | (908) | (614) |
| Net Cash From Operating Activities | 9,581 | 10,533 | 7,901 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,777) | (1,885) | (2,177) |
| Acquisitions of businesses and technologies, net of cash acquired | 0 | (187) | (42) |
| Proceeds from business dispositions | 48 | 134 | 58 |
| Purchases of investment securities | (185) | (173) | (83) |
| Proceeds from sales of investment securities | 152 | 77 | 10 |
| Other | 22 | 26 | 19 |
| Net Cash From (Used in) Investing Activities | (1,740) | (2,008) | (2,215) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt, net and other | 47 | (204) | 2 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 7 | 4 | 1,281 |
| Repayments of long-term debt and debt with maturities over 3 months | (753) | (48) | (1,333) |
| Purchases of common shares | (3,795) | (2,299) | (403) |
| Proceeds from stock options exercised | 167 | 255 | 245 |
| Dividends paid | (3,309) | (3,202) | (2,560) |
| Other | 0 | 0 | (11) |
| Net Cash From (Used in) Financing Activities | (7,636) | (5,494) | (2,779) |
| Effect of exchange rate changes on cash and cash equivalents | (122) | (70) | 71 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 83 | 2,961 | 2,978 |
| Cash and Cash Equivalents, Beginning of Year | 9,799 | 6,838 | |
| Cash and Cash Equivalents, End of Year | 9,882 | 9,799 | 6,838 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,864 | 1,941 | 970 |
| Interest paid | 563 | 544 | 549 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2022 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2022 10-K (Filed: Feb 17, 2023) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2022 | Dec 31, 2021 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $ 9,882 | 9,799 |
| Investments, primarily bank time deposits and U.S. treasury bills | 288 | 450 |
| Trade receivables, less allowances of 2022: $500; 2021: $519 | 6,218 | 6,487 |
| Inventories: | ||
| Finished products | 3,805 | 3,081 |
| Work in process | 680 | 694 |
| Materials | 1,688 | 1,382 |
| Total inventories | 6,173 | 5,157 |
| Other prepaid expenses and receivables | 2,663 | 2,346 |
| Total current assets | 25,224 | 24,239 |
| Investments | 766 | 816 |
| Property and equipment, at cost: | ||
| Land | 511 | 525 |
| Buildings | 4,053 | 4,007 |
| Equipment | 14,164 | 13,528 |
| Construction in progress | 1,484 | 1,304 |
| Property and equipment, at cost | 20,212 | 19,364 |
| Less: accumulated depreciation and amortization | 11,050 | 10,405 |
| Net property and equipment | 9,162 | 8,959 |
| Intangible assets, net of amortization | 10,454 | 12,739 |
| Goodwill | 22,799 | 23,231 |
| Deferred income taxes and other assets | 6,033 | 5,212 |
| Total Assets | 74,438 | 75,196 |
| Liabilities and Shareholders Investment | ||
| Current liabilities: | ||
| Trade accounts payable | 4,607 | 4,408 |
| Salaries, wages and commissions | 1,556 | 1,625 |
| Other accrued liabilities | 5,845 | 5,181 |
| Dividends payable | 887 | 831 |
| Income taxes payable | 343 | 306 |
| Current portion of long-term debt | 2,251 | 754 |
| Total current liabilities | 15,489 | 13,105 |
| Long-term debt | 14,522 | 17,296 |
| Post-employment obligations and other long-term liabilities | 7,522 | 8,771 |
| Commitments and contingencies | ||
| Shareholders investment: | ||
| Preferred shares, one dollar par value Authorized 1,000,000 shares, none issued | 0 | 0 |
| Common shares, without par value Authorized 2,400,000,000 shares Issued at stated capital amount Shares: 2022: 1,986,519,278; 2021: 1,985,273,421 | 24,709 | 24,470 |
| Common shares held in treasury, at cost Shares: 2022: 248,724,257; 2021: 221,191,228 | (15,229) | (11,822) |
| Earnings employed in the business | 35,257 | 31,528 |
| Accumulated other comprehensive income (loss) | (8,051) | (8,374) |
| Total Abbott Shareholders Investment | 36,686 | 35,802 |
| Noncontrolling interests in subsidiaries | 219 | 222 |
| Total Shareholders Investment | 36,905 | 36,024 |
| Total Liabilities and Shareholders' Investment | 74,438 | 75,196 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |